Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma

Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive disease characterized by its metastatic potential and chemoresistance. These traits are partially attributable to the highly tumorigenic pancreatic cancer stem cells (PaCSCs). Interestingly, these cells show unique features in order...

Full description

Bibliographic Details
Main Authors: Beatriz Parejo-Alonso, Alba Royo-García, Pilar Espiau-Romera, Sarah Courtois, Álvaro Curiel-García, Sladjana Zagorac, Isabel Villaoslada, Kenneth P. Olive, Christopher Heeschen, Patricia Sancho
Format: Article
Language:English
Published: Elsevier 2023-02-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Pancreatic Ductal Adenocarcinoma
ALK
Receptor Tyrosine Kinases
Cancer Stem Cells
Chemoresistance
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222015517

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222015517

Similar Items